Seegene Inc
상단으로
Contact Us

Not Available for sale in the United States

  • Real-time
    PCR
  • CE-IVD
    marked

Anyplex™ II
HPV HR Detection

Simultaneous detection of 14 high-risk HPV genotypes in a single reaction

Anyplex™Ⅱ HPV HR Detection simultaneously detects, differentiates and quantifies 14 high-risk HPV genotypes including HPV16 and HPV18 which are implicated as major risk factors for cervical cancer. Based on Seegene’s proprietary DPO™ and TOCE™ technologies, this assay performs on multiplex real-time PCR instrument and enables accurate screening test of HPV infection in a single reaction.

Key Features and Benefits

  • Multiplex real-time PCR

    Detection of 14 high-risk HPV genotypes in a single reaction

  • Automatic data analyzer

    Automated data interpretation and LIS interlocking with Seegene Viewer

  • User-friendly workflow

    Convenient workflow using Seegene’s automated one platform

  • Quantitative analysis

    Quantitative analysis by cyclic-CMTA

  • Useful monitoring

    Useful tool for surveillance and infection control

  • UDG system

    Utilization of the UDG system to prevent carry-over contamination

  • Proper patient care

    Quick and proper treatment provided by accurate test results

  • Automatic data analyzer

    Automated data interpretation and LIS interlocking with Seegene Viewer

  • Whole process validation

    Whole process validation from extraction to PCR by whole process control

  • Analytes

    Anyplex™ II
    HPV HR Detection

    14 High-risk HPV types
    • Human Papillomavirus 16 (HPV 16)
    • Human Papillomavirus 18 (HPV 18)
    • Human Papillomavirus 31 (HPV 31)
    • Human Papillomavirus 33 (HPV 33)
    • Human Papillomavirus 35 (HPV 35)
    • Human Papillomavirus 39 (HPV 39)
    • Human Papillomavirus 45 (HPV 45)
    • Human Papillomavirus 51 (HPV 51)
    • Human Papillomavirus 52 (HPV 52)
    • Human Papillomavirus 56 (HPV 56)
    • Human Papillomavirus 58 (HPV 58)
    • Human Papillomavirus 59 (HPV 59)
    • Human Papillomavirus 66 (HPV 66)
    • Human Papillomavirus 68 (HPV 68)
    • Internal Control (IC)
  • Specimens

    • Liquid based cytology (e.g., ThinPrep® and Surepath™)
    • Cervical swab
    • Self-collected vaginal
  • Ordering Information

    Product
    Cat No. / Size
    Anyplex™ II HPV HR Detection
    HP10380Z / 25 rxns [1]
    HP7E00X / 100 rxns

Result

The result represents co-infection that HPV 16 is low (+) in the HEX channel, HPV 18 is intermediate (++) in the Quasar 670 channel.

Publication

- High-Risk human papillomavirus genotype distribution in the Northern region of Portugal: Data from regional cervical cancer screening program

- Comparison of the performance of Anyplex II HPV HR, the Cobas 4800 human papillomavirus test and Hybrid Capture 2

- Clinical validation of Anyplex™ II HPV HR Detection according to the guidelines for HPV test requirements for cervical cancer screening

- Predominance of High-Risk Human Papillomavirus Genotype 16 and 39 in Women with Premalignant and Malignant Cervical Pathology from Raipur, Chhattisgarh: Clinical Evaluation of Tagging Oligonucleotide Cleavage and Extension Mediated Genotyping Assay

- 2020 list of human papillomavirus assays suitable for primary cervical cancer screening

- A Technical Comparison of Human Papillomavirus Genotyping Assays from a Population-Based Cervical Cancer Screening in South Central Ethiopia

- Impact of high-risk Human Papillomavirus genotyping in cervical disease in the Northern region of Portugal: Real-world data from regional cervical cancer screening program

- Detection of HPV in urine for cervical cancer screening: feasibility of an assay system

- Detection of 14 High-risk Human Papillomavirus (HPV) Genotypes Within the Italian Cervical Cancer Screening

- Allplex HPV HR Detection assay fulfils all clinical performance and reproducibility validation requirements for primary cervical cancer screening

- High-risk HPV prevalence and vaccination coverage among Indigenous women in the Colombian Amazon: Implications for cervical cancer prevention. Cross-sectional study

Note

[1]